C. diff Risk


Oral Bioavailability


Approximate Cost


Spectrum Of Activity


2g IV q8h for severe infections

eGFR 0 - 10eGFR 10 - 50eGFR > 502g IV q24h3-4g IV daily divided q8-12h2g IV q8h

0.5-2g IV load then 500mg IV q12h

Give after dialysis on dialysis days

Peritoneal Dialysis 1-2g IV q12h3-4g IV daily divided q8-12h

(Dose as per eGFR 10-50)

General Information

Common Usage

Therapy of gram negative infections including Pseudomonas, particularly in patients with penicillin and cephalosporin allergy or when there is no alternative susceptible agent

Drug Monitoring

Monitor liver enzymes

Adverse Effects

  •  Elevated liver enzymes

  •  Cytopenias

  •  Eosinophilia

  •  Phlebitis at injection site

  •  Rash/allergy

  •  CNS toxicity

Major Interactions

No significant interactions.

Additional Information

RESTRICTED - Available via Health Canada Special Access Program only

For special access drug availability contact:

IV Administration

  • Dilute in 50-100 mL D5W or NS and administer over 30-60 min.

  • Max concentration 20 mg/mL.

Community IV Formulary (Metro Area)


Antimicrobial class: Monobactam

Pregnancy category: B

Average serum half life: 2 hours

Biliary penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic